BriaCell Therapeutics (BCTX) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edesa Biotech (EDSA) has outperformed BriaCell Therapeutics (BCTX) over the past year, gaining 17.6% versus a loss of 61.7%. Over five years, EDSA leads with a -95.6% price change compared with -97.0% for BCTX. Edesa Biotech is the larger company by market cap ($27.0 million vs $26.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | EDSA |
|---|---|---|
| Share price | $3.06 | $2.00 |
| Market cap | $26.72M | $27.02M |
| 1-day change | -3.32% | -8.05% |
| YTD return | -56.96% | +40.85% |
| 1-year return | -61.75% | +17.65% |
| 5-year return | -97.00% | -95.63% |
| EPS (TTM) | $-6.97 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-34.90M | $-7.19M |
| 52-week high | $13.09 | $20.32 |
| 52-week low | $2.60 | $0.72 |
| Distance from 52-week high | -76.62% | -90.16% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +716.50% |
| Average volume | 250.81K | 1.45M |
| Shares outstanding | 8.73M | 13.51M |
| Employees | — | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed BCTX by 79.4 percentage points over the past year.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
BCTX vs EDSA FAQ
Which is bigger, BriaCell Therapeutics or Edesa Biotech?
Edesa Biotech (EDSA) is larger, with a market capitalization of $27.02M compared with $26.72M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, BCTX or EDSA?
EDSA returned +17.65% over the past 12 months, compared with -61.75% for BCTX (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and Edesa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.